Patents Assigned to PAR Pharmaceutical, Inc.
  • Vareniciline compound and process of manufacture thereof
    Patent number: 11872234
    Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: January 16, 2024
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
  • Vareniciline compound and process of manufacture thereof
    Patent number: 11779587
    Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: October 10, 2023
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
  • Varenicline compound and process of manufacture thereof
    Patent number: 11717524
    Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: August 8, 2023
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
  • Varenicline compound and process of manufacture thereof
    Patent number: 11602537
    Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 14, 2023
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
  • Epinephrine formulations
    Patent number: 11337938
    Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: May 24, 2022
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Suketu Sanghvi, Vinayagam Kannan, Matthew Kenney
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 11207372
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: December 28, 2021
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 11135265
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: October 5, 2021
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Pre-filled syringe containing sugammadex
    Patent number: 11097023
    Abstract: A method for providing a sterile pharmaceutical composition in a pre-filled syringe, the method including solubilizing an active agent and a pH adjusting agent in a solvent to provide a pharmaceutical composition, filtering the pharmaceutical composition through a membrane to provide a sterile pharmaceutical composition, and providing the sterile pharmaceutical composition in a pre-filled syringe having a labeled size, wherein the active agent includes sugammadex, the pre-filled syringe has a headspace volume that is less than 7.5% of the labeled size, and the method is free of a heat-based sterilization process. Also provided are sterile pharmaceutical compositions prepared according to the method.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: August 24, 2021
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Atul Arvind Bodkhe, Satish Shamlal Patil, Jatin Jagdish Gajjar
  • Method to treat hypotension using vasopressin in certain genotypes
    Patent number: 10920278
    Abstract: The present disclosure relates to a method of treating a patient experiencing hypotension, comprising genotyping for a TT, AA, or AT genotype, and administering a therapeutically effective amount of vasopressin based on genotype to maintain a target blood pressure.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: February 16, 2021
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventor: Saji Vijayan
  • Method to treat hypotension using vasopressin in certain genotypes
    Patent number: 10844435
    Abstract: The present disclosure relates to a method of treating a patient experiencing hypotension, comprising genotyping for a TT, AA, or AT genotype, and administering a therapeutically effective amount of vasopressin based on genotype to maintain a target blood pressure.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: November 24, 2020
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventor: Saji Vijayan
  • Epinephrine formulations
    Patent number: 10624864
    Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: April 21, 2020
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Suketu Sanghvi, Vinayagam Kannan, Matthew Kenney
  • Epinephrine formulations
    Patent number: 10130592
    Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: November 20, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Vinayagam Kannan, Patrick Irish, Michael Bergren
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 10010575
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: July 3, 2018
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9993520
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: June 12, 2018
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9981006
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 29, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9974827
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 22, 2018
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9968649
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 15, 2018
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9962422
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 8, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9937223
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 10, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Vasopressin formulations for use in treatment of hypotension
    Patent number: 9925233
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 27, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi